Evidence map›Paper›PMID 36193172›Full record

ArticleEClinicalMedicine2022

An evaluation of global Chikungunya clinical management guidelines: A systematic review.

Eika Webb, Melina Michelen, Ishmeala Rigby, Andrew Dagens, Dania Dahmash, Vincent Cheng, Reena Joseph, Samuel Lipworth, Eli Harriss, Erhui Cai and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Bone erosions and joint damage caused by chikungunya virus: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2024
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Chikungunya and Dengue Encephalitis: A Critical Narrative Review.Annals of Indian Academy of Neurology · 2025
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 2 countries.

Eika WebbLiverpool School of Tropical Medicine, Pembroke Pl, Liverpool, UK.
Melina MichelenInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Ishmeala RigbyInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Andrew DagensInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Dania DahmashInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Vincent ChengBristol Medical School, University of Bristol, Bristol, UK.
Reena JosephImperial College London, London, UK.
Samuel LipworthOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Eli HarrissBodleian Health Care Libraries, University of Oxford, Oxford, UK.
Erhui CaiInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Robert NartowskiInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Pande Putu JanuragaUdayana University, Bali, Indonesia.
Keerti GedelaImperial College London, London, UK.
Evi SukmaningrumAtma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Muge CevikDepartment of Global Health and Infection Research, School of Medicine, University of St Andrews, Fife, Scotland, UK.
Helen GrovesWellcome Trust, Euston Rd, London, UK.
Peter HartWellcome Trust, Euston Rd, London, UK.
Tom FletcherLiverpool School of Tropical Medicine, Pembroke Pl, Liverpool, UK.
Lucille BlumbergNational Institute for Communicable Diseases, Johannesburg, South Africa.
Peter W HorbyInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
Shevin T JacobLiverpool School of Tropical Medicine, Pembroke Pl, Liverpool, UK.
Louise SigfridInternational Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical Medicine, University of Oxford, Oxford, UK.
University of Oxford · GBLiverpool School of Tropical Medicine · GBImperial College London · GBWellcome Trust · GBAtma Jaya Catholic University of Indonesia · IDNational Institute for Communicable DiseasesUdayana University · IDUniversity of Bristol · GBUniversity of St Andrews · GB

Funding

Medical Research Council MR/T001151/1Wellcome Trust
6 · The paper itself

Abstract

Background: Chikungunya virus (CHIKV) has expanded its geographical reach in recent decades and is an emerging global health threat. CHIKV can cause significant morbidity and lead to chronic, debilitating arthritis/arthralgia in up to 40% of infected individuals. Prevention, early identification, and clinical management are key for improving outcomes. The aim of this review is to evaluate the quality, availability, inclusivity, and scope of evidence-based clinical management guidelines (CMG) for CHIKV globally. Methods: We conducted a systematic review. Six databases were searched from Jan 1, 1989, to 14 Oct 2021 and grey literature until Sept 16, 2021, for CHIKV guidelines providing supportive care and treatment recommendations. Quality was assessed using the appraisal of Guidelines for Research and Evaluation tool. Findings are presented in a narrative synthesis. PROSPERO registration: CRD42020167361. Findings: 28 CMGs were included; 54% (15/28) were produced more than 5 years ago, and most were of low-quality (median score 2 out of 7 (range 1-7)). There were variations in the CMGs' guidance on the management of different at-risk populations, long-term sequelae, and the prevention of disease transmission. While 54% (15/28) of CMGs recommended hospitalisation for severe cases, only 39% (11/28) provided guidance for severe disease management. Further, 46% (13/28) advocated for steroids in the chronic phase, but 18% (5/28) advised against its use. Interpretation: There was a lack of high-quality CMGs that provided supportive care and treatment guidance, which may impact patient care and outcomes. It is essential that existing guidelines are updated and adapted to provide detailed evidence-based treatment guidelines for different at-risk populations. This study also highlights a need for more research into the management of the acute and chronic phases of CHIKV infection to inform evidence-based care. Funding: The UK Foreign, Commonwealth and Development Office, Wellcome Trust [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135].

Indexed as

AGREE IIChikungunyaClinical management guidelinesEmerging infectionsSupportive care

Identifiers

PMID36193172
PMCPMC9526181
OpenAlexW4297502260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.